Palmar plantar erythrodysesthesia epidemiology and demographics: Difference between revisions
| Line 7: | Line 7: | ||
PPE occurs in 6-42% of patients receiving chemotherapy. | PPE occurs in 6-42% of patients receiving chemotherapy. | ||
Several authors have reported that the incidence of PLD-associated hand and foot syndrome for patients with any grade of PPE is about 50% and for patients with grade 3 and grade 4 PPE the incidence is about 20% <ref name="pmid14998846">{{cite journal| author=O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A et al.| title=Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. | journal=Ann Oncol | year= 2004 | volume= 15 | issue= 3 | pages= 440-9 | pmid=14998846 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14998846 }}</ref>, <ref name="pmid11454878">{{cite journal| author=Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ| title=Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. | journal=J Clin Oncol | year= 2001 | volume= 19 | issue= 14 | pages= 3312-22 | pmid=11454878 | doi=10.1200/JCO.2001.19.14.3312 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11454878 }}</ref>, for a PLD dose of 50 mg/m2 every 4 weeks. | Several authors have reported that the incidence of PLD-associated hand and foot syndrome for patients with any grade of PPE is about 50% and for patients with grade 3 and grade 4 PPE the incidence is about 20% <ref name="pmid14998846">{{cite journal| author=O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A et al.| title=Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. | journal=Ann Oncol | year= 2004 | volume= 15 | issue= 3 | pages= 440-9 | pmid=14998846 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14998846 }}</ref>, <ref name="pmid11454878">{{cite journal| author=Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ| title=Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. | journal=J Clin Oncol | year= 2001 | volume= 19 | issue= 14 | pages= 3312-22 | pmid=11454878 | doi=10.1200/JCO.2001.19.14.3312 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11454878 }}</ref>, for a PLD dose of 50 mg/m2 every 4 weeks. According to evidence, it has been determined that a dose of 40 mg/m2 every 4 weeks is at present considered equally effective and less toxic. This dose has become the preferred dosage<ref name="pmid17229768">{{cite journal| author=Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G| title=Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). | journal=Ann Oncol | year= 2007 | volume= 18 | issue= 7 | pages= 1159-64 | pmid=17229768 | doi=10.1093/annonc/mdl477 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17229768 }}</ref>. | ||
==References== | ==References== | ||
{{reflist|3}} | {{reflist|3}} | ||
Revision as of 00:21, 30 September 2018
|
Palmar plantar erythrodysesthesia Microchapters |
|
Differentiating Palmar plantar erythrodysesthesia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Palmar plantar erythrodysesthesia epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Palmar plantar erythrodysesthesia epidemiology and demographics |
|
FDA on Palmar plantar erythrodysesthesia epidemiology and demographics |
|
CDC on Palmar plantar erythrodysesthesia epidemiology and demographics |
|
Palmar plantar erythrodysesthesia epidemiology and demographics in the news |
|
Blogs on Palmar plantar erythrodysesthesia epidemiology and demographics |
|
Directions to Hospitals Treating Palmar plantar erythrodysesthesia |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Palmar Plantar Erythrodysesthesia or Hand-Foot syndrome is a skin-related reaction involving the palms an soles. It commonly occurs due to a reaction to different kinds of chemotherapeutic agent used to treat cancer. The first s. PPE may be classified into grade1, grade 2, grade 3, or grade 4 depending on toxicity rating. The pathophysiologic mechanism of Palmar Plantar Erythrodysesthesia is under active investigation and different mechanisms have been postulated. Histologic biopsy is consistent with toxic reaction[1]. After extensive studies, it has been determined that Pegylated Liposomal doxorubicin deposits into the eccrine glands which is concentrated in the palms and soles which then causes a drug reaction and development of PPE.[2] Several Different types of Chemotherapeutic agents have been associated with the development of Palmar Plantar Erythrodysesthesia. PPE must be differentiated from Acute Graft Versus Host Response, Tinea manuum and Hand-Foot reaction due to tyrosine kinase inhibitor.
Epidemiology and demographics
PPE occurs in 6-42% of patients receiving chemotherapy.
Several authors have reported that the incidence of PLD-associated hand and foot syndrome for patients with any grade of PPE is about 50% and for patients with grade 3 and grade 4 PPE the incidence is about 20% [3], [4], for a PLD dose of 50 mg/m2 every 4 weeks. According to evidence, it has been determined that a dose of 40 mg/m2 every 4 weeks is at present considered equally effective and less toxic. This dose has become the preferred dosage[5].
References
- ↑ Baack BR, Burgdorf WH (1991). "Chemotherapy-induced acral erythema". J Am Acad Dermatol. 24 (3): 457–61. PMID 2061446.
- ↑ Lademann J, Martschick A, Kluschke F, Richter H, Fluhr JW, Patzelt A; et al. (2014). "Efficient prevention strategy against the development of a palmar-plantar erythrodysesthesia during chemotherapy". Skin Pharmacol Physiol. 27 (2): 66–70. doi:10.1159/000351801. PMID 23969763.
- ↑ O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A; et al. (2004). "Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer". Ann Oncol. 15 (3): 440–9. PMID 14998846.
- ↑ Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ (2001). "Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan". J Clin Oncol. 19 (14): 3312–22. doi:10.1200/JCO.2001.19.14.3312. PMID 11454878.
- ↑ Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G (2007). "Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome)". Ann Oncol. 18 (7): 1159–64. doi:10.1093/annonc/mdl477. PMID 17229768.